Product Description
An IgG3 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Chimeric anti-phosphotidylserine monoclonal antibody binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bavituximab)
Mechanisms of Action: Angiogenesis Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Avid Bioservices
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Glioblastoma|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
STU 102017-015 | P2 |
Active, not recruiting |
Hepatocellular Carcinoma |
2023-04-21 |
|
NCT03139916 | P2 |
Completed |
Glioblastoma |
2022-08-31 |